GTC/Ovation's genetically engineered ATryn approved in US
This article was originally published in Scrip
Executive Summary
GTC Biotherapeutics/Ovation Pharmaceuticals' ATryn (antithrombin III [recombinant]) became the first US-licensed medicine derived from a genetically engineered (GE) animal following the US FDA's approval on February 6th for patients with hereditary antithrombin deficiency.